News
-
ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204
-
ONL Therapeutics Announces First-in-human Clinical Study With ONL1204
-
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 Into First-in-Human Clinical Study
-
ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First In Human Clinical Trials
-
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases
-
Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug
-
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
-
ONL Therapeutics Gets Federal Grant of $1 Million
-
After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials